WASHINGTON (Reuters) - Novartis will further restrict access to its irritable bowel syndrome drug Zelnorm, reserving it for the sickest patients, the company and U.S. health regulators said on ...

Mar. 23 -- FRIDAY, March 30 (HealthDay News) -- Zelnorm, a drug to treat constipation associated with irritable bowel syndrome, has been taken off the market because of an increased risk of heart ...

COVINGTON, La., June 30, 2022 /PRNewswire/ -- Alfasigma USA, Inc. announces the withdrawal of the NDA for ZELNORM ® (tegaserod) effective June 30 th. Alfasigma USA, Inc. will no longer make the ...

Novartis AG’s irritable bowel drug Zelnorm will come with a new warning that patients could experience severe diarrhea that requires hospital treatment, U.S. regulators said Wednesday. The drug’s new ...

Following the example of the west, health regulators in China have issued an order saying that Novartis' irritable bowel syndrome drug Zelmac to be withdrawn from the market. Following the example of ...

Aug. 26, 2004 — The U.S. Food and Drug Administration (FDA) has approved tegaserod maleate for chronic idiopathic constipation, docetaxel in combination with doxorubicin and cyclophosphamide for ...

Zelnorm, the constipation drug pulled from the market earlier this year over fears it raised the risks of heart attack and stroke, will be available to some patients, the FDA said this morning. Women ...

LONDON (CBS.MW) -- Swiss pharmaceutical Novartis said a study presented at the 2004 United European Gastroenterology Week shows its Zelnorm irritable bowel syndrome drug is effective and ...

BEDMINSTER, N.J., July 23, 2020 (GLOBE NEWSWIRE) -- Alfasigma USA, Inc. today announced a strategic deal with Indegene, Inc., a global life sciences and healthcare solutions provider, to co-promote ...

How can you convince sufferers to seek treatment with a new drug if they don't understand the problem it can solve? This was one of the key consumer challenges faced by Novartis in establishing ...

It is ORDERED that effective August 1, 2009, the provisions of the Court's September 8, 2008 Order regarding the centralized management of all pending and future New Jersey state court litigation ...